Prezcobix® (darunavir/cobicistat) once-daily tablets for HIV-1 treatment

What Prezcobix® Is and How It Works

Prezcobix® combines darunavir and cobicistat in one tablet for the treatment of HIV‑1 infection. It is taken with other antiretroviral medicines. The fixed dose is 800 mg darunavir plus 150 mg cobicistat, often noted as prezcobix 800 150 mg. Many people compare options when searching for prezcobix without insurance and value once‑daily dosing.

Youdrugstore is a licensed Canadian pharmacy headquartered in Manitoba; prescriptions are reviewed by licensed pharmacists before dispensing, and you can order online or by phone with chat support during office hours.

Drug class: darunavir is an HIV‑1 protease inhibitor, and cobicistat is a pharmacokinetic booster. Mechanism of action: darunavir blocks viral protease, which prevents cleavage of gag‑pol polyproteins and produces immature, noninfectious virus. Cobicistat inhibits CYP3A metabolism to raise darunavir levels and maintain effective exposure. Indication: adults and adolescents who meet weight criteria, used in combination with other antiretrovirals.

Limitations: not recommended in patients with known darunavir resistance‑associated substitutions or with severe hepatic impairment. Avoid use with strong CYP3A inducers or with other boosted protease inhibitors. For full details, consult the prezcobix package insert and prezcobix prescribing information.

Dosage and Usage

• Standard dose: one Prezcobix 800/150 mg tablet once daily with food, together with other antiretrovirals.
• Swallow tablets whole. Do not crush, split, or chew.
• Use the same dose in eligible adolescents who meet the labeled weight threshold per prescribing information.
• Do not coadminister with ritonavir or with products containing cobicistat, or with other boosted protease inhibitors.
• Missed dose: if less than 12 hours late, take the tablet with food as soon as possible, then resume the regular schedule. If more than 12 hours late, skip the missed dose and take the next dose at the usual time.
• If vomiting occurs within 1 hour of dosing, take another tablet; if after 1 hour, do not repeat the dose.
• Drug interactions are common due to CYP3A effects. Contraindicated medications include strong CYP3A inducers (for example rifampin, carbamazepine, phenytoin, St. John’s wort) and certain CYP3A substrates where increased levels pose serious risk (for example simvastatin, lovastatin, lurasidone, triazolam, oral midazolam, pimozide, and ergot derivatives). Review all prescriptions, OTC products, and supplements.
• Renal monitoring is advised if used with tenofovir disoproxil fumarate due to cobicistat effects on creatinine and tubular function. Hepatic labs may be needed in those with underlying liver disease.

• Store at 20–25 °C (68–77 °F); excursions 15–30 °C (59–86 °F).
• Keep in the original, tightly closed bottle with the desiccant to protect from moisture.
• Store out of reach of children and away from humidity.
• For travel, keep tablets in your carry‑on with the pharmacy label. Avoid leaving the bottle in hot cars or direct sun.
• Pack extra doses and a copy of your prescription for delays.

Benefits and Savings

Prezcobix helps simplify therapy by combining a protease inhibitor and booster in one tablet. Once‑daily dosing with food supports adherence and reduces pill burden. Darunavir has a high genetic barrier to resistance, which is useful for many treatment‑naïve patients and select treatment‑experienced patients without darunavir resistance.

Ordering from a Canadian pharmacy can reduce the prezcobix cost compared with typical U.S. pricing. Many customers save 60–80% on their monthly supply, even prezcobix without insurance. Multi‑month supplies and periodic bulk promotions can further lower per‑month costs.

We source through licensed, vetted international partner pharmacies to offer authentic brand medications, a broad selection, and affordable pricing.

For extra value, see our prezcobix coupon page for current promotions.

Side Effects and Safety

• Common: diarrhea, nausea, abdominal pain, headache, fatigue, and rash.
• Lab changes: elevated liver enzymes, lipid changes, and increases in serum creatinine due to cobicistat’s effect on tubular secretion.
• Other: cough, dizziness, or insomnia may occur in some patients.

Serious or uncommon risks include severe skin reactions (Stevens‑Johnson syndrome/toxic epidermal necrolysis or DRESS), hepatotoxicity, and immune reconstitution inflammatory syndrome. Darunavir contains a sulfonamide moiety; use caution in those with sulfa allergy. New or worsening renal impairment can occur, especially when combined with tenofovir disoproxil fumarate. Many significant drug interactions exist; check contraindications and adjust therapy as needed.

Onset Time

With consistent daily dosing and an active background regimen, viral load often begins to decline within 2–4 weeks. Many patients reach substantial suppression by 8–24 weeks, depending on baseline viral load, adherence, and the overall regimen. CD4 counts typically rise over months. Individual responses vary, and regular lab monitoring helps track progress.

Compare With Alternatives

Many patients start therapy with integrase inhibitor–based regimens. For those already suppressed on a two‑drug maintenance regimen, Juluca® (dolutegravir/rilpivirine) is an option when criteria are met. It does not require a booster and uses a different drug class than darunavir.

Raltegravir is another integrase inhibitor used with other antiretrovirals. Isentress® may be dosed once or twice daily depending on the formulation and companion drugs. It has a distinct interaction profile compared with boosted protease inhibitors like darunavir/cobicistat.

Some patients use darunavir boosted with ritonavir instead of cobicistat, particularly during pregnancy or when drug‑interaction considerations favor ritonavir. Choice depends on resistance testing, comorbidities, drug interactions, and individualized treatment goals.

Combination Therapy

• Common backbones include emtricitabine plus tenofovir alafenamide, or abacavir plus lamivudine when appropriate.
• Avoid combining with other boosted protease inhibitors or with products containing cobicistat or ritonavir.
• Monitor renal function if used with tenofovir disoproxil fumarate; consider alternatives in renal impairment.
• Review interacting medications and adjust doses or select alternatives to maintain safety.

Patient Suitability and Cost-Saving Tips

Good candidates include adults and adolescents who meet weight criteria and have no known darunavir resistance‑associated substitutions. Prezcobix is not recommended in severe hepatic impairment. It is generally avoided during pregnancy because cobicistat can lower darunavir exposure in the second and third trimesters; alternative boosting with ritonavir is often preferred.

Careful review of concomitant medications is essential due to CYP3A interactions. Contraindicated or restricted drugs include strong inducers and several sensitive substrates. Those with chronic hepatitis B or C may need closer hepatic monitoring. Use caution with a history of severe cutaneous reactions or sulfa allergy.

To manage the prezcobix cash price, consider ordering a multi‑month supply to reduce per‑month costs. You can set gentle reorder reminders so you do not run out. Periodic prezcobix discount events and bulk promotions may help if paying prezcobix out of pocket. These options are available whether using benefits or purchasing prezcobix without insurance.

Authoritative Sources

Janssen Prescribing Information for Prezcobix

Health Canada Drug Product Database: Prezcobix Product Monograph

FDA Prescribing Information for Prezcobix

Order Prezcobix® from Youdrugstore: add to cart, upload your prescription, and we ship with prompt, express, cold-chain handling.

This material is educational and does not replace professional medical advice. Always consult your healthcare provider about diagnosis, treatment, and potential drug interactions.